FBN 4MG Pill - white round, 6mm
Generic Name: futibatinib
Pill with imprint FBN 4MG is White, Round and has been identified as Lytgobi 4 mg. It is supplied by Taiho Oncology, Inc.
Lytgobi is used in the treatment of Cholangiocarcinoma and belongs to the drug class multikinase inhibitors. Lytgobi 4 mg is not a controlled substance under the Controlled Substances Act (CSA).
Images for FBN 4MG
Lytgobi
- Generic Name
- futibatinib
- Imprint
- FBN 4MG
- Strength
- 4 mg
- Color
- White
- Size
- 6.00 mm
- Shape
- Round
- Availability
- Prescription only
- Drug Class
- Multikinase inhibitors
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Taiho Oncology, Inc.
- National Drug Code (NDC)
- 64842-0120
See also:
Pemazyre
Pemazyre is used to treat certain types of bile duct cancer and myeloid/lymphoid neoplasms ...
Alecensa
Alecensa (alectinib) is an oral kinase inhibitor that may be used to treat certain types of ...
Botox
Botox is used for cosmetic purposes and to treat overactive bladder symptoms, urinary incontinence ...
Alunbrig
Alunbrig (brigatinib) is used to treat anaplastic lymphoma kinase-positive (ALK+) metastatic ...
Augtyro
Augtyro (repotrectinib) is a next-generation TKI (Tyrosine Kinase Inhibitor) cancer medicine used ...
Ayvakit
Ayvakit (avapritinib) is a prescription medicine used for the treatment of gastrointestinal stromal ...
Balversa
Balversa (erdafitinib) is an oral kinase inhibitor that may be used to treat adults with locally ...
Braftovi
Braftovi is a targeted cancer treatment used in combination with Mektovi, mFOLFOX6, or Erbitux, to ...
Cabometyx
Cabometyx is used to treat advanced kidney cancer, liver cancer, thyroid cancer, and pancreatic and ...
More about Lytgobi (futibatinib)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Imprints, shape & color data
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: multikinase inhibitors
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.